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Abstract
Introduction: The aim of this study was to develop and validate a prognostication model to predict overall and breast 
cancer specific survival for women treated for early breast cancer in the UK.
Methods: Using the Eastern Cancer Registration and Information Centre (ECRIC) dataset, information was collated for 
5,694 women who had surgery for invasive breast cancer in East Anglia from 1999 to 2003. Breast cancer mortality 
models for oestrogen receptor (ER) positive and ER negative tumours were derived from these data using Cox 
proportional hazards, adjusting for prognostic factors and mode of cancer detection (symptomatic versus screen-
detected). An external dataset of 5,468 patients from the West Midlands Cancer Intelligence Unit (WMCIU) was used for 
validation.
Results: Differences in overall actual and predicted mortality were <1% at eight years for ECRIC (18.9% vs. 19.0%) and 
WMCIU (17.5% vs. 18.3%) with area under receiver-operator-characteristic curves (AUC) of 0.81 and 0.79 respectively. 
Differences in breast cancer specific actual and predicted mortality were <1% at eight years for ECRIC (12.9% vs. 13.5%) 
and <1.5% at eight years for WMCIU (12.2% vs. 13.6%) with AUC of 0.84 and 0.82 respectively. Model calibration was 
good for both ER positive and negative models although the ER positive model provided better discrimination (AUC 
0.82) than ER negative (AUC 0.75).
Conclusions: We have developed a prognostication model for early breast cancer based on UK cancer registry data 
that predicts breast cancer survival following surgery for invasive breast cancer and includes mode of detection for the 
first time. The model is well calibrated, provides a high degree of discrimination and has been validated in a second UK 
patient cohort.
Introduction
Accurate prediction of survival is an essential part of the
decision making process following surgery for early
breast cancer and allows clinicians to determine which
patients will benefit from adjuvant therapy. At present
these decisions are largely based on known pathological
prognostic factors that retain independent significance
on multivariate analysis including tumour size, tumour
grade and lymph node status in addition to the efficacy of
any adjuvant therapy. The predicted treatment benefit
can be calculated by applying the relative risk reduction
of a particular adjuvant therapy to the breast cancer spe-
cific mortality for an individual patient to give an absolute
percentage survival benefit for that patient.
The Nottingham Prognostic Index (NPI), a prognostic
scoring system based on a large cohort of patients with
early breast cancer treated in a single institution, is based
on tumour size, grade and lymph node status and when
first described divided patients into three groups with
significantly different survival [1]. The NPI has been pro-
spectively validated in a second Nottingham dataset [2],
as well as in other centres [3], and now allocates patients
to one of six prognostic groups [4]. More recently a
model has been developed to allow prediction of survival
* Correspondence: gordon.wishart@addenbrookes.nhs.uk
1Cambridge Breast Unit, Addenbrooke's Hospital, Hills Road, Cambridge, CB2 
2QQ, UK
† Contributed equally© 2010 Wishart et al., licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Wishart et al, Breast Cancer Research 2010, 12:R1
http://breast-cancer-research.com/content/12/1/R1
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vival of the six groups previously described [5].
Adjuvant! is a web-based prognostication and treat-
ment benefit tool for breast cancer that is now widely
used in the UK to help clinicians and patients make deci-
sions about adjuvant therapy. The mortality estimates
used in Adjuvant! were based on 10-year observed overall
survival (OS) of women aged 36 to 69 who were diag-
nosed between 1988 and 1992 and recorded in the Sur-
veillance, Epidemiology and End Results (SEER) registry
[6]. Breast cancer specific survival (BCSS) without adju-
vant therapy was calculated based on estimates of the
number of patients likely to have received systemic ther-
apy and the risk reductions outlined in the Early Breast
Cancer Trialists' Collaborative Group [7,8]. Although
these assumptions have now been validated in a popula-
tion-based Canadian dataset [9] there has always been
some uncertainty about how applicable the Adjuvant!
model is to contemporary patients diagnosed and treated
in the UK. A recent paper has shown that Adjuvant! over-
estimated the overall survival by 6% in a UK cohort of
1,065 women with early breast cancer treated in Oxford
between 1986 and 1996 [10].
The primary aim of this study therefore was to develop
a prognostication model to predict OS from a large
cohort of UK women diagnosed in East Anglia from 1999
to 2003 using cancer registration and OS data recorded
by the Eastern Cancer Registration and Information Cen-
tre (ECRIC). ECRIC provides near complete breast can-
cer registration for 10 hospitals in East Anglia as well as
information on systemic treatment and mode of detec-
tion. A secondary aim of this study was to validate the
model in a second UK cancer registry dataset to facilitate
development of an online prognostication and treatment
benefit tool for UK-based patients with early breast can-
cer.
Materials and methods
Study population
The primary analysis was based on data from patients
with invasive breast cancer diagnosed in East Anglia, UK
between 1999 and 2003 identified by ECRIC. ECRIC cov-
ers a catchment area population of approximately 5.5 mil-
lion people and registers all malignant tumours occurring
in people resident in East Anglia at the time of diagnosis.
ECRIC also records prospectively demographic, patho-
logic, staging, general treatment and outcome informa-
tion. Death certificate flagging through the Office of
National Statistics provides the registries with notifica-
tion of deaths. The lag times for this are a few weeks for
cancer deaths and two months to a year for non-cancer
deaths. In addition, ECRIC checked vital status by query-
ing the National Health Service Strategic Tracing Service.
Vital status was ascertained at the end of June 2008 and
all analyses were censored on 31 December 2007 to allow
for delay in reporting of vital status. Breast cancer spe-
cific mortality was defined as deaths where breast cancer
was listed as the cause of death on Parts 1a, 1b, or 1c of
the death certificate.
Information obtained from ECRIC included age at
diagnosis, number of lymph nodes sampled and number
of lymph nodes positive (categorised as 0, 1, 2 to 4, 5 to 9,
and 10+ nodes positive), tumour size (categorised as <10
mm, 10 to 19 mm, 20 to 29 mm, 30 to 49 mm, 50+ mm),
histological grade (I, II, III), oestrogen receptor (ER) sta-
tus (positive or negative), mode of detection (screening
vs. clinical), information on local therapy (wide local exci-
sion, mastectomy, radiotherapy), and type of adjuvant
systemic therapy (chemotherapy, endocrine therapy,
both). Exact chemotherapy regimens are unknown, but
the majority of breast cancer patients in the ECRIC popu-
lation received first or second generation chemotherapy
during this time period. Patients who did not undergo
surgery, patients with incomplete local therapy (wide
local excision without radiotherapy) and patients with
fewer than four nodes excised with a diagnosis of node-
negative disease were excluded from the analyses, leaving
a study population of 5,694 individuals (Table 1).
An independent validation dataset was comprised of
women diagnosed with invasive breast cancer between
1999 and 2003 within the boundaries of the West Mid-
lands Cancer Intelligence Unit (WMCIU). The geo-
graphic area served by WMCIU has a population of
approximately 5.3 million individuals. Identical patient
demographic information and study endpoints were
retrieved from the WMCIU cancer registration database,
with the same exclusions applied as for the ECRIC data-
set. The total validation study population included 5,468
individuals (Table 1). As this was a large population-
based study, with full anonymisation of all data, informed
consent and ethical approval was not sought.
Prognostic model parameters
Breast cancer specific mortality and mortality from other
causes (competing mortality) were modelled separately.
For breast cancer specific mortality, a Cox proportional
hazards model was used to estimate the hazard ratio
associated with each prognostic factor. As the effect of ER
status varies over time [11] ER negative and ER positive
tumours were modelled separately. Nodal status, tumour
grade and tumour size were modelled both as categorical
variables and as ordinal variables. The models with ordi-
nal variables fit the data better, and so these were chosen
for the final models. Chemotherapy, endocrine therapy,
and tumour detection by screening were treated as simple
indicator variables. For the purposes of this study, screen-
detected cancers were those discovered by screening
mammography in the NHS Breast Screening Programme
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validation (West Midlands Cancer Intelligence Unit-WMCIU) cohorts
ECRIC WMCIU
Total Number of Subjects 5,694 5,468
Total time at risk (years) 31,904 25,917
Median follow-up (years)* 5.65 (0.04 to 8.00)† 4.85 (0.07 to 8.00)†
Number of breast cancer deaths 737 668
Number of other deaths 338 287
Annual breast cancer mortality rate 0.023 (0.021 to 0.025)‡ 0.026 (0.024 to 0.028)‡
Five-year breast cancer survival rate 0.89 (0.88 to 0.90)‡ 0.88 (0.87 to 0.89)‡
Median age at diagnosis, years 58 (23 to 95)† 58 (22 to 93)†
Number Number
Age, years
<35 111 2 108 2
35 to 49 1,172 21 1,195 22
50 to 64 2,630 46 2,393 44
65 to 74 1,124 20 1,101 20
75+ 657 12 671 12
Nodal status
0 3,532 62 3,184 58
1 741 13 746 14
2 to 4 806 14 792 14
5 to 9 380 7 451 8
10+ 235 4 295 5
Tumour size, mm
<10 625 11 485 9
10 to 19 2,310 41 2,136 39
20 to 29 1,627 29 1,566 29
30 to 49 845 15 923 17
50+ 287 5 358 7
Grade
I 1,005 18 1,017 19
II 2,927 51 2,442 45
III 1,762 31 2,009 37
Oestrogen Receptor (ER) Status
ER negative 991 17 1,116 20
ER positive 4,703 83 4,352 80
Adjuvant therapy
Chemotherapy 1,905 33 2,121 39
Endocrine therapy 4,268 75 2,406 44
Combined chemoendocrine 1,122 20 579 11
Screen detected
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Page 4 of 10Yes 1,621 28 1,256 23
No 4,073 72 4,212 77
* Follow-up censored at eight years
† Range of variable
‡ 95 CI
Table 1: Patient characteristics for model development (Eastern Cancer Registration and Information Centre-ECRIC) and 
validation (West Midlands Cancer Intelligence Unit-WMCIU) cohorts (Continued)
which at the time offered three-yearly mammography to standard Chi-squared test. Model discrimination was
women aged 50 to 64. In an exploratory analysis, age at
diagnosis was included as a categorical variable in five age
groups (<40, 40 to 49, 50 to 59, 60 to 69 and 70+) but
these were not found to be significantly associated with
breast specific mortality (data not shown) and age was
excluded from subsequent models.
Competing mortality was modelled separately and
adjusted for age at diagnosis. Exploration of the age spe-
cific beta-coefficients suggested that the effect varied
exponentially with age; the best fit model was age to the
power of 2.38.
Model discrimination and calibration
We used the baseline survivor function from the ER neg-
ative and ER positive Cox proportional hazards models
for breast cancer specific survival adjusted for the other
prognostic factors to estimate the predicted number of
deaths from breast cancer. Deaths from other causes were
estimated from the baseline survivor function for com-
peting mortality after adjusting for age. The total number
of deaths at Years 5 and 8 after diagnosis was estimated
by summing the breast-specific and competing mortality.
Observed and predicted deaths were compared using a
evaluated by calculating the area under the receiver-oper-
ator-characteristic (ROC) curve (AUC) calculated for
breast cancer specific and overall deaths at Year 8 past
diagnosis. The ROC curve plots sensitivity against 1-
specificity at different predicted risk thresholds. Model
calibration was assessed using a simplified goodness-of-
fit (GOF) method for the Cox proportional hazards
model proposed by May and Hosmer [12] in which
observed and model-based estimated deaths at Year 8
after diagnosis within deciles of risk score were com-
pared. This provides a goodness of fit Chi-square test. As
the baseline hazards and prognostic variable coefficients
differed for ER positive and ER negative models, separate
GOF tests were carried out for these models. In subgroup
analyses, where numbers within deciles of risk score were
small, quartiles of risk scores were used. Person-years lost
were calculated by taking the area under the cumulative
risk curve. Analyses were performed using STATA, ver-
sion 9.2 (StataCorp, College Station, TX, USA).
Table 2: Hazard ratios (95% CI) and model coefficients (standard errors) for prognostic factors included in the development 
models
ER Positive Model ER Negative Model
Prognostic Factor Hazard 
ratio
95% CI Coefficient SE Hazard 
ratio
95% CI Coefficient SE
Number Positive Nodes*
(0, 1, 2 to 4, 5 to 9, 10+) 1.75 1.62 to 1.89 0.56 0.04 1.55 1.44 to 1.68 0.44 0.04
Tumour Size, mm*
(<10, 10 to 19, 20 to 29, 30 to 49, 50+) 1.43 1.30 to 1.58 0.36 0.05 1.45 1.29 to 1.63 0.37 0.06
Tumour Grade* 1.43 1.30 to 1.58 0.36 0.05 1.45 1.29 to 1.63 0.37 0.06
(Low, Intermediate, High) 1.43 1.30 to 1.58 0.36 0.05 1.45 1.29 to 1.63 0.37 0.06
Detection by Screening 0.70 0.53 to 0.92 -0.36 0.14 0.86 0.56 to 1.32 -0.15 0.22
Chemotherapy 0.73 0.60 to 0.89 -0.31 0.1 0.82 0.62 to 1.08 -0.2 0.14
Hormone therapy 0.95 0.74 to 1.23 -0.05 0.13 1.43 1.09 to 1.89 0.36 0.14
* modeled as ordinal continuous
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Initial model fit
The ECRIC data set was used to derive the primary prog-
nostic models for breast specific and competing mortal-
ity. Beta-coefficients and standard errors for each
prognostic factor in both the ER negative and ER positive
models are provided in Table 2. The estimated relative
hazard associated with treatment with adjuvant hormone
therapy was smaller than the published estimate based on
randomised clinical trials [7,8] in women with ER positive
tumours, and was associated with a poorer prognosis in
women with ER negative tumours where no effect is
expected based on clinical trial data. These differences
are likely to represent bias due to clinical selection or
patient non-compliance in the observational data.
As expected, this model was well calibrated. The model
tended to over-predict mortality, but the difference
between actual and predicted deaths was less than one
percent at five and eight years after diagnosis (14.8 vs.
15.6 percent and 18.9 vs. 19.0 percent, respectively), dif-
ferences that were not statistically significant (P = 0.10
and 0.83 respectively). There were 31,904 person-years of
follow-up compared to 31,662 predicted. Model discrimi-
nation was also good - the calculated area under the ROC
curve (AUC) for the overall model was 0.81 (SE 0.0074)
(Table 3). Similarly, breast cancer specific actual and pre-
dicted mortality were within one percent at Years 5 and 8
past diagnosis (10.6 vs. 11.0 percent, P = 0.28 and 12.9 vs.
13.5 percent, P = 0.26, respectively; AUC = 0.84, SE =
0.008) (Additional file 1, Table S2). The ER positive and
ER negative prognostic models were also well-calibrated
overall and for all subgroups, and the goodness of fit tests
suggest that the models fit well across different risk cate-
gories. The ER positive model provided better discrimi-
nation (AUC = 0.82, SE = 0.0111) than the ER negative
model (AUC = 0.75, SE = 0.0171).
Validation
The WMCIU study population of 5,468 individuals was
used for independent prognostic model validation. Over-
Table 3: Overall actual and predicted mortality in Eastern Cancer Registration and Information Centre cohort
Year 5 deaths* Year 8 deaths*
Group N % A P† Mortality
Difference
A P† Mortality
Difference
AUC SE
Total 5,694 100.00 841 890 0.86 1,075 1,082 0.12 0.81 0.007
Age, years
<35 111 1.95 28 23 4.5 31 27 3.6 0.83 0.044
35 to 49 1,172 20.58 150 171 1.79 187 209 1.88 0.81 0.017
50 to 64 2,630 46.19 270 289 0.72 354 359 0.19 0.80 0.013
65 to 74 1,124 19.74 176 191 1.33 227 233 0.53 0.79 0.019
75+ 657 11.54 217 216 0.15 276 254 3.35 0.68 0.021
Nodal status
Negative 3,532 62.03 297 350 1.5 408 433 0.71 0.76 0.013
Positive 2,162 37.97 544 541 0.14 667 649 0.83 0.80 0.010
Tumour size, mm
<10 625 10.98 30 39 1.44 41 49 1.28 0.75 0.038
10 to 19 2,310 40.57 194 222 1.21 267 280 0.56 0.75 0.017
20 to 29 1,627 28.57 277 283 0.37 363 347 0.98 0.79 0.013
30 to 49 845 14.84 215 226 1.3 259 270 1.3 0.76 0.018
50+ 287 5.04 125 119 2.09 145 136 3.14 0.82 0.024
Grade
I 1,005 17.65 38 64 2.59 55 82 2.69 0.76 0.035
II 2,927 51.40 331 357 0.89 455 445 0.34 0.77 0.013
III 1,762 30.94 472 470 0.11 565 555 0.57 0.77 0.012
Oestrogen Receptor (ER) Status
Negative 991 17.40 321 318 0.3 364 353 1.11 0.77 0.016
Positive 4,703 82.60 520 572 1.11 711 729 0.38 0.80 0.009
* Number of deaths after censoring follow up at five and eight years after diagnosis.
† Predicted number of deaths rounded to nearest whole number
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predict mortality was slightly worse than with the ECRIC
data but the difference between actual and predicted
mortality was still small (<2 percent) at five years past
diagnosis (15.8 vs. 17.4 percent, P = 0.004) and less than
one percent at Year 8 past diagnosis (17.5 vs. 18.4 percent,
P = 0.11) (Table 4). There were 25,917 person-years of
follow-up compared to 25,809 person-years predicted.
The overall model AUC was calculated as 0.79 (SE =
0.0079). Breast cancer specific actual and predicted mor-
tality were within two percent at Years 5 and 8 past diag-
nosis (11.0 vs. 12.6 percent and 12.2 vs. 13.6 percent,
respectively; AUC = 0.82, SE = 0.0083) (Additional file 1,
Table S1).
Overall, the ER positive and ER negative prognostic
models were well-calibrated, although both models pre-
dict more breast cancer deaths than observed. The over-
estimation was slightly greater for the ER negative model
than the ER positive model. In ER negative disease, the
Year 8 actual breast cancer mortality rate was 25.0 per-
cent compared to 30.6 percent predicted; for ER positive
tumours, Year 8 actual and predicted breast cancer mor-
Table 4: Overall actual and predicted mortality in West Midland Cancer Intelligence Unit (WMCIU) cohort
Year 5 deaths* Year 8 deaths*
Group N % A P† Mortality
Difference
A P† Mortality
Difference
AUC SE
Total 5,468 100 862 950 1.61 955 1006 0.93 0.79 0.008
Age, years
<35 108 1.98 21 24 2.78 28 26 1.85 0.70 0.057
35 to 49 1,195 21.85 153 185 2.68 175 201 2.18 0.79 0.018
50 to 64 2,393 43.76 279 311 1.34 310 334 1 0.80 0.013
65 to 74 1,101 20.14 198 203 0.45 218 217 0.09 0.76 0.018
75+ 671 12.27 211 216 0.75 224 228 0.6 0.72 0.021
Nodal status
Negative 3,184 58.23 265 333 2.14 301 357 1.76 0.74 0.015
Positive 2,284 41.77 597 606 0.39 654 648 0.26 0.75 0.011
Tumour size, mm
<10 485 8.87 27 32 1.03 29 34 1.03 0.82 0.040
10 to 19 2,136 39.06 173 216 2.01 196 233 1.73 0.76 0.018
20 to 29 1,566 28.64 259 274 0.96 286 295 0.57 0.71 0.017
30 to 49 923 16.88 257 258 0.11 272 276 0.43 0.72 0.018
50+ 358 6.55 146 160 3.91 156 168 3.35 0.72 0.027
Grade
I 1,017 18.6 66 67 0.1 75 72 0.29 0.79 0.029
II 2,442 44.66 314 318 0.16 359 344 0.61 0.77 0.013
III 2,009 36.74 482 554 3.58 521 589 3.38 0.75 0.012
Oestrogen 
Receptor (ER) 
Status
Negative 1,116 20.41 317 364 4.21 341 380 3.49 0.76 0.016
Positive 4,352 79.59 545 575 0.69 614 625 0.25 0.78 0.010
* Number of deaths after censoring follow up at five and eight years after diagnosis.
† Predicted number of deaths rounded to nearest whole number
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all model fit was good (GOF P-values > 0.05), although
the fit was less good for some sub-groups. Specifically, for
ER positive disease, the fit was not so good in women
aged <35 years (GOF P = 0.01) and 35 to 49-year-old age
category (P = 0.045). For ER negative disease, the model
fit in node negative disease (GOF P = 0.03), 30 to 49 mm
tumours size category (GOF P = 0.02) and high grade
tumours (GOF P = 0.001) was not so good (Additional file
1, Table S2).
Model discrimination was also good, again being some-
what better for the ER positive model (AUC = 0.81, SE =
0.0111) than the ER negative model (AUC = 0.75, SE =
0.0169). There were no significant differences between
the ROC curves generated with the ECRIC and WMCIU
data (ER positive χ2 = 0.17, P = 0.68, ER negative χ2 = 0.00,
P = 0.95) (Figure 1).
We also explored the overall and breast cancer specific
mortality within T1N0 and T2N0 good prognosis sub-
groups where decisions regarding adjuvant therapy can
be difficult and challenging (Additional file 1, Table S3).
In the WMCIU population, 1,931 individuals were diag-
nosed with T1N0 tumours, while 1,182 individuals were
diagnosed with T2N0 tumours. For T1N0 tumours,
actual and predicted five- and eight-year overall mortality
rates were within 2.1 percent (5.5 vs. 7.6 percent and 6.1
vs. 8.2 percent, respectively); actual and predicted five-
and eight-year breast cancer specific mortality rates were
within one percent (2.4 vs. 3.3 percent and 2.8 vs. 3.6 per-
cent, respectively). For T2N0 tumours, actual and pre-
dicted five- and eight-year overall mortality was within
2.5 percent (11.7 vs. 14.1 percent and 13.5 vs. 15.2 per-
cent, respectively); actual and predicted five- and eight-
year breast cancer specific mortality was within one per-
cent (7.9 vs. 8.7 percent and 9.1 vs. 9.4 percent, respec-
tively).
Summary comparison of overview vs. model-derived 
therapy benefit estimates
Given the difference in the estimates of the effects of hor-
mone therapy from the ECRIC dataset compared to pub-
lished clinical trial data, we also fit models (constrained
models) with the relative hazard of hormone therapy con-
strained to the published estimate from the 1998 over-
views (relative hazard 0.68 for ER positive tumours).
Under this constrained model, the coefficient estimates
for the other prognostic factor coefficients were similar
to the original, data-driven model (Additional file 1, Table
S4). Performance of the constrained model was slightly
poorer in the ECRIC data than the full data driven model
(Table 5), but the difference between actual and predicted
mortality at eight years and between actual and predicted
person-years of follow-up was still small. In the WMCIU
validation dataset, the constrained model performed bet-
Receiver operator characteristic curves for breast cancer specific mortality by Oestrogen Receptor status in Eastern Cancer Reg-istration and Inf mation Centre and West Midlands Cancer Intelligence Unit cohortsFigure 1 Rec iver oper t r chara teristic curves for breast canc r sp cific mortalit  by Oestrogen R ceptor status in Eastern  -
istration and Information Centre and West Midlands Cancer Intelligence Unit cohorts. A) ER positive at five years, B) ER negative at five years, 
C) ER positive at eight years, D) ER negative at eight years. Solid line ECRIC data; dashed line WMCIU data.
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year mortality and person-years of follow-up.
Finally, we tested the performance of models using the
data derived coefficients for grade, node status, tumour
size and mode of detection from the full and constrained
models with the benefit estimates from the 1998 over-
views (Table 5). First generation chemotherapy benefit
estimates were applied in all these analyses. Again the
models performed slightly poorer than the full, data-
driven model in the ECRIC dataset, but somewhat better
in the WMCIU validation dataset.
Discussion
We have developed a prognostication model for early
breast cancer based on data collated from a large number
of patients within a single UK cancer registry. The model
was validated using data from a second UK registry. As
both model and validation datasets contain over 5,000
patients this model is likely to be predictive of overall sur-
vival for all women diagnosed with early breast cancer in
the UK. The model was well calibrated and provides a
high degree of discrimination across different prognostic
groups. A particular strength of this project was the abil-
ity to access breast cancer specific mortality from ECRIC,
based on death certificate reporting rather than being
estimated from population data.
Accurate prediction of survival, and subsequent calcu-
lation of treatment benefit, has become increasingly
sophisticated in the management of early breast cancer in
the UK. Although the introduction of the NPI allowed
risk stratification into five then six [4] prognostic groups,
the original models provided survival estimates based on
the average survival for each individual group. Further-
more, the model was based on treatment from a single
institution where individual treatment bias may have an
effect on overall survival. Despite this potential short-
coming, the NPI has been successfully validated in exter-
nal datasets [3] and has now been further developed to
include more individual survival prediction based on
individual rather than group NPI scores [5].
The publication of the Adjuvant! prognostication and
treatment benefit tool in 2001 led to widespread and early
adoption in the UK. The web-based system allowed free
access and was recognised as being user friendly for both
clinicians as well as patients with breast cancer. Adjuvant!
was seen to provide several advantages over and above
the NPI including individual survival predictions and cal-
culation of potential treatment benefits for that patient.
The use of coloured bar charts to display this information
facilitated the often difficult discussions surrounding sys-
temic adjuvant therapies with patients and allowed the
development of treatment thresholds for chemotherapy
in individual breast units.
The Adjuvant! model is based on population data col-
lected by the Surveillance, Epidemiology and End Results
(SEER) registry [6]. Breast cancer specific survival (BCSS)
without adjuvant therapy was calculated based on esti-
mates of the number of patients likely to have received
systemic therapy and the risk reductions outlined in the
Early Breast Cancer Trialists' Collaborative Group [7,8].
Table 5: Comparison of mortality and person-years lost for data-derived and constrained models in development and 
validation cohorts
All cause mortality Breast specific mortality Person-Years Lost
ECRIC
Model:
Hormone 
coefficient
Chemotherapy 
coefficient
A P ROC A P ROC Total 
Possible PY‡
A P
Full Model Model 1,075 1,082 0.81 737 768 0.84 35,003 3,099 3,341
Full Overview* Overview 1,075 984 0.81 737 660 0.83 35,003 3,099 3,030
Constrained Model† Model 1,075 980 0.81 737 656 0.83 35,003 3,099 3,061
Constrained Overview Overview 1,075 990 0.81 737 667 0.83 35,003 3,099 3,089
WMCIU
Model:
Full Model Model 955 1,006 0.79 668 743 0.82 28,322 2,405 2,513
Full Overview Overview 955 956 0.79 668 690 0.81 28,322 2,405 2,376
Constrained Model† Model 955 952 0.78 668 685 0.81 28,322 2,405 2,406
Constrained Overview Overview 955 965 0.78 668 699 0.81 28,322 2,405 2,436
*Application of overview estimates is performed by setting the model-derived therapy coefficient to zero. Overview-derived therapy risk reductions (first generation) are then applied in
the life table analysis. The risk reductions are only applied to individuals who actually received therapy. No Overview hormone therapy benefit was applied to individuals with ER- tumors.
†Under the constrained model, the model coefficient for adjuvant hormone therapy is the same as the Overview estimate.
‡Follow-up was censored at eight years
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used to generate this model, as well as breast cancer spe-
cific mortality. Breast cancer registration is close to 100
percent for both SEER and ECRIC data across specific
geographic regions. This may limit their generalisability,
but the good performance of the model based on ECRIC
data in an independent dataset from a different region of
the UK and validation of Adjuvant! using data from a
population registry from Canada [9] suggests that this is
not likely to be a significant problem.
A key aim that underpinned development of this model
was to develop a prognostication and treatment benefit
tool that benefited from the many attributes of the Adju-
vant! model but which was specifically tailored to the UK
population. UK cancer registries have near complete pro-
spective data collection on breast cancer registration,
pathological features, treatment and death notification.
The ECRIC data used in this study included all female
breast cancer cases that were treated surgically and were
fully characterised for mode of detection, tumour size
and grade, lymph node and ER status and details of adju-
vant therapy. ECRIC collects data from more than 10
hospitals in East Anglia including only two teaching hos-
pitals with strong research activity. As a result the data
collected by ECRIC are likely to be representative of the
UK as a whole and reflect good practise rather than best
practise and was an ideal data source on which to base the
initial model.
In addition, the success of the NHS Breast Screening
Programme in the UK has meant that there has been a
shift to better prognostic groups at diagnosis than previ-
ously. Two recent papers, have suggested that screen
detection confers an additional survival benefit beyond
stage shift and reduces the risk of systemic recurrence
when compared with symptomatic cancers of a similar
stage [13,14]. Although the majority of the survival
advantage associated with breast screening can be
explained by this shift to an earlier stage at diagnosis,
recent evidence suggests that approximately 25 percent of
the survival advantage is still unexplained [15]. Introduc-
tion of mode of detection (screen-detected versus symp-
tomatic) was therefore a key requirement for this model,
as was adjustment of the nodal status groups with cre-
ation of a single node positive group. The inclusion of a
group with a single positive node will allow these patients
to have more accurate survival prediction than previ-
ously, as prognosis in Adjuvant! is based on the average of
the one to three node positive group.
The model performs well across all prognostic groups
in the development (ECRIC) dataset except in patients ≥
75 years old, where the predicted mortality at Year 8 past
diagnosis was less than observed (250 predicted vs. 276
actual deaths). This was also seen in the validation
(WMCIU) data. In these data the model also predicted a
more favourable outcome than observed for low grade
tumours and a less favourable outcome than observed for
high grade and ER negative tumours.
A key decision, when considering the application of this
model as a predictor of treatment benefit, is whether to
use the data-derived coefficients for hormone therapy or
chemotherapy or the benefit estimates from published
overview data [7,8]. The application of the overview esti-
mates to the full model was a strong predictor of both
eight-year mortality and person-years follow-up in the
WMCIU validation dataset and has the advantage of
allowing regular updates as further overview results are
published.
Conclusions
In conclusion we have developed a prognostication
model for early breast cancer based on data from a UK
cancer registry that has included mode of detection for
the first time. The model is well calibrated, provides a
high degree of discrimination and has been validated in a
second UK patient cohort. This model, together with
application of published relative risk reductions for sys-
temic therapy, will underpin a new web-based prognosti-
cation and treatment benefit tool for early breast cancer
in the UK.
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